Annual jab for HIV protection passes trial hurdle
Lenacapavir, which stops HIV from replicating inside cells, has passed early safety tests.
Lenacapavir, which stops HIV from replicating inside cells, has passed early safety tests.
Data from half-a-million people was assessed by the University of Aberdeen research team.
It can be taken at home on a daily basis, but it is only patients for who have tried all other options.
Routine screening invitations were not sent because of an error dating back to 2008.
Broadening access to cladribine should help more patients avoid hospital and free up clinic time.
Paediatricians studied 21 children in the UK and Ireland who became very ill after the icy drinks.
Patients given drugs for movement disorders like restless leg syndrome say their behaviour changed entirely.
Frequent donors were more likely to have different genetic changes in their blood stem cells, scientists found.
Former cabinet minister says it would be ludicrous to suggest he tried to shortcut safety checks in the pandemic.